Targeting cancer with peptide aptamers

Renaud Seigneuric; Jessica Gobbo; Pierre Colas; Carmen Garrido

doi:10.18632/oncotarget.297

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

Targeting cancer with peptide aptamers

Renaud Seigneuric _, Jessica Gobbo, Pierre Colas and Carmen Garrido

PDF | HTML | How to cite

Oncotarget. 2011; 2:557-561. https://doi.org/10.18632/oncotarget.297

Metrics: PDF 3105 views | HTML 6154 views | ?

Abstract

Renaud Seigneuric^1,2, Jessica Gobbo^1,2, Pierre Colas³, Carmen Garrido^1,2

¹Heat Shock Proteins and Cancer, INSERM, UMR 866 IFR 100, Faculty of Medicine, 7 Boulevard Jeanne D'Arc, 21000 Dijon, France

²Université de Bourgogne, Dijon, France

³CNRS USR 3151, P2I2 Group, Station Biologique, Roscoff, Bretagne, France

Received: June 22, 2011; Accepted: June 24, 2011; Published: June 24, 2011;

Correspondence:

Renaud Seigneuric, email:

Abstract

A major endeavour in cancer chemotherapy is to develop agents that specifically target a biomolecule of interest. There are two main classes of targeting agents: small molecules and biologics. Among biologics (e.g.: antibodies), DNA, RNA but also peptide aptamers are relatively recent agents. Peptide aptamers are seldom described but represent attractive agents that can inhibit a growing panel of oncotargets including Heat Shock Proteins. Potential pitfalls and coming challenges towards successful clinical trials are presented such as optimizing the delivery of peptide aptamers thanks to Nanotechnology.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 297

Publication Alerts

Research Perspectives:

Targeting cancer with peptide aptamers

Abstract